glp-1 drug market size Pharma Giants Bet on Next-Generation Treatments to Sustain Growth GLP-1 Receptor Agonist Market: Exploring

p = 0.01 in patients with eGFR 60 ml/min/1.73 m 2 the changes of thoracic fluid index after liraglutide and placebo were similar (0.2 [95%CI ( 8.9)(9.2)] and 1.1 [95%CI ( 0.9)(3.0)], respectively) ( p = 0.50)

SGLT-2, sodium-glucose cotransporter-2

doi: 10.3350/cmh.2025.0744, 51

[Google Scholar] 69.Choi IY, Lee JS, Kim JK, Lee SH, Kim YH, Park YJ, et al

But none had been isolated with incretin-like properties first described by La Barre which was considered to be ideal for the treatment of type 2 diabetes (Marks Samols

Further studies are warranted to assess the exact site of absorption and the optimal dosage for the desired action with tolerable adverse effects